Extrawell Pharmaceutical Holdings Ltd - ESG Rating & Company Profile powered by AI
If you are employed by Extrawell Pharmaceutical Holdings Ltd and you would like to licence your Sustainability aseessment, please get in touch. Jump to the bottom of the webpage for potential risks for Extrawell Pharmaceutical Holdings Ltd based on sector, geography and size. This ESG score includes 17 UN SDGs including: 'No Poverty', 'Climate Action' and 'Life below Water'.
Extrawell Pharmaceutical Holdings Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.0; made up of an environmental score of 4.0, social score of 5.3 and governance score of 2.7.
4.0
Medium ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
989 | Spectrum Pharmaceuticals Inc | 4.1 | High |
989 | Tricida Inc | 4.1 | High |
1004 | Extrawell Pharmaceutical Holdings Ltd | 4.0 | High |
1004 | Can B Corp | 4.0 | High |
1004 | CLS Holdings USA Inc | 4.0 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Extrawell Pharmaceutical Holdings Ltd have an accelerator or VC vehicle to help deliver innovation?
Does Extrawell Pharmaceutical Holdings Ltd disclose current and historical energy intensity?
Does Extrawell Pharmaceutical Holdings Ltd report the average age of the workforce?
Does Extrawell Pharmaceutical Holdings Ltd reference operational or capital allocation in relation to climate change?
Does Extrawell Pharmaceutical Holdings Ltd disclose its ethnicity pay gap?
Does Extrawell Pharmaceutical Holdings Ltd disclose cybersecurity risks?
Does Extrawell Pharmaceutical Holdings Ltd offer flexible work?
Does Extrawell Pharmaceutical Holdings Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Extrawell Pharmaceutical Holdings Ltd disclose the number of employees in R&D functions?
Does Extrawell Pharmaceutical Holdings Ltd conduct supply chain audits?
Does Extrawell Pharmaceutical Holdings Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Extrawell Pharmaceutical Holdings Ltd conduct 360 degree staff reviews?
Does Extrawell Pharmaceutical Holdings Ltd disclose the individual responsible for D&I?
Does Extrawell Pharmaceutical Holdings Ltd disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Extrawell Pharmaceutical Holdings Ltd disclose current and / or historical scope 2 emissions?
Does Extrawell Pharmaceutical Holdings Ltd disclose water use targets?
Does Extrawell Pharmaceutical Holdings Ltd have careers partnerships with academic institutions?
Did Extrawell Pharmaceutical Holdings Ltd have a product recall in the last two years?
Does Extrawell Pharmaceutical Holdings Ltd disclose incidents of discrimination?
Does Extrawell Pharmaceutical Holdings Ltd allow for Work Councils/Collective Agreements to be formed?
Has Extrawell Pharmaceutical Holdings Ltd issued a profit warning in the past 24 months?
Does Extrawell Pharmaceutical Holdings Ltd disclose parental leave metrics?
Does Extrawell Pharmaceutical Holdings Ltd disclose climate scenario or pathway analysis?
Does Extrawell Pharmaceutical Holdings Ltd disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Extrawell Pharmaceutical Holdings Ltd disclose the pay ratio of women to men?
Does Extrawell Pharmaceutical Holdings Ltd support suppliers with sustainability related research and development?
Does Extrawell Pharmaceutical Holdings Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Extrawell Pharmaceutical Holdings Ltd reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Extrawell Pharmaceutical Holdings Ltd involved in embryonic stem cell research?
Does Extrawell Pharmaceutical Holdings Ltd disclose GHG and Air Emissions intensity?
Does Extrawell Pharmaceutical Holdings Ltd disclose its waste policy?
Does Extrawell Pharmaceutical Holdings Ltd report according to TCFD requirements?
Does Extrawell Pharmaceutical Holdings Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Extrawell Pharmaceutical Holdings Ltd disclose energy use targets?
Does Extrawell Pharmaceutical Holdings Ltd disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Extrawell Pharmaceutical Holdings Ltd have a policy relating to cyber security?
Have a different question?
Potential Risks for Extrawell Pharmaceutical Holdings Ltd
These potential risks are based on the size, segment and geographies of the company.
Extrawell Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, distributes, and sells pharmaceutical products in the People's Republic of China. The company operates through Manufacturing, Trading, and Gene Development segments. It offers transfer factor oral solution, a dual immune regulator for the treatment of diseases caused by virus infection and weak cellular immune system; and Wisk for the treatment of II-III degree of radio-injury of skin, normal common burn, actinic dermatitis, various infectious ulcers, and oral ulcers, as well as for trauma and post operation wound healing. The company also provides ZhouBang, a thromboxane synthetase inhibitor to prevent the coagulation of platelets and facilitate relaxation of blood vessels. In addition, it is involved in the marketing and distribution of imported pharmaceutical products, including Millibar for the treatment of high blood pressure; and development of oral insulin. Further, the company engages in the commercial exploitation and development of genome-related technology; provision of agency services; property investment business; and holding of gene invention rights. Extrawell Pharmaceutical Holdings Limited is headquartered in Quarry Bay, Hong Kong.